Data from the MYTHIC trial presented at a conference setting reported a 60% objective response rate at the proposed recommended phase 2 dose (RP2D) in patients with CCNE1-amplified platinum-resistant ovarian cancer treated with lunresertib plus zedoresertib. In the overall population across dose levels, investigators reported an ORR of 37.5%. The study also reported tumor shrinkage in 80% of patients and durability signals, including 37% of patients remaining on treatment beyond 16 weeks. The company reported additional partial responses observed after the data cutoff. The FDA has granted fast track designation for the regimen in adults with CCNE1-amplified or specific deleterious ovarian cancer contexts, positioning the trial for faster regulatory engagement if subsequent datasets confirm benefit and safety.